ASCEND-HF Trial

Summary: Randomized 7141 patients to nesiritide versus placebo. While nesiritide did improve the symptom of dyspnea better than placebo, there was no reduction in 30 day rehospitalization and no mortality benefit. Hypotension was significant in the nesiritide group.

Original Publication:

N Engl J Med 2011; 365:32-43 July 7, 2011

Eponym: Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure